Chilton Capital Management LLC Has $30.99 Million Holdings in AstraZeneca PLC $AZN

Chilton Capital Management LLC boosted its stake in AstraZeneca PLC (NASDAQ:AZN) by 1.6% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 403,925 shares of the company’s stock after purchasing an additional 6,312 shares during the period. Chilton Capital Management LLC’s holdings in AstraZeneca were worth $30,989,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AZN. NewSquare Capital LLC lifted its stake in shares of AstraZeneca by 149.3% in the second quarter. NewSquare Capital LLC now owns 364 shares of the company’s stock worth $25,000 after acquiring an additional 218 shares during the period. Richardson Financial Services Inc. raised its holdings in AstraZeneca by 59.8% during the 2nd quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock worth $28,000 after purchasing an additional 149 shares during the last quarter. Rakuten Investment Management Inc. bought a new position in AstraZeneca during the 3rd quarter worth approximately $31,000. FSA Wealth Management LLC lifted its position in shares of AstraZeneca by 376.0% in the 2nd quarter. FSA Wealth Management LLC now owns 476 shares of the company’s stock worth $33,000 after purchasing an additional 376 shares during the period. Finally, VSM Wealth Advisory LLC bought a new stake in shares of AstraZeneca in the 2nd quarter valued at $33,000. 20.35% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

AZN has been the subject of a number of analyst reports. Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a research note on Wednesday, January 21st. Morgan Stanley reiterated an “overweight” rating and set a $103.00 price target on shares of AstraZeneca in a report on Wednesday, December 3rd. Barclays reissued an “overweight” rating on shares of AstraZeneca in a research report on Tuesday, January 6th. TD Cowen reaffirmed a “buy” rating on shares of AstraZeneca in a research note on Tuesday, December 9th. Finally, Guggenheim reiterated a “buy” rating on shares of AstraZeneca in a report on Wednesday, December 3rd. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, AstraZeneca presently has an average rating of “Moderate Buy” and an average target price of $95.75.

AstraZeneca Stock Up 1.4%

AZN stock opened at $94.23 on Tuesday. The stock’s 50 day simple moving average is $91.97 and its 200 day simple moving average is $83.84. The company has a market cap of $292.28 billion, a P/E ratio of 31.31, a price-to-earnings-growth ratio of 1.59 and a beta of 0.34. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.69 and a current ratio of 0.88. AstraZeneca PLC has a fifty-two week low of $61.24 and a fifty-two week high of $96.51.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Thursday, November 6th. The company reported $1.19 EPS for the quarter, beating the consensus estimate of $1.14 by $0.05. AstraZeneca had a return on equity of 32.89% and a net margin of 16.17%.The firm had revenue of $15.19 billion during the quarter, compared to the consensus estimate of $14.75 billion. During the same quarter in the previous year, the company posted $2.08 earnings per share. The company’s quarterly revenue was up 12.0% on a year-over-year basis. On average, research analysts expect that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.